Rare diseases
Investigational molecules
Locations
Recruiting trials first
12 clinical trials in this condition
Denmark
Poland
GermanyGermanyIn short
Diagnosing osteosarcoma requires a combination of careful evaluation, imaging studies, and tissue testing to confirm the presence of this aggressive bone cancer and determine the best course of treatment.
Understanding when to seek medical attention for possible osteosarcoma is crucial for early detection and better outcomes. Anyone experiencing persistent bone pain that doesn't go away, especially pain that worsens at night or during physical activity, should consult a healthcare professional. This is particularly important for teenagers and young adults, as osteosarcoma most commonly affects people in this age group, though it can occur at any age.
Specific warning signs include swelling near a bone or joint that doesn't improve, limited movement in a joint, or a noticeable lump that feels warm to the touch. Sometimes the first symptom can be an unexpected bone fracture from minor trauma, occurring because the affected bone has become weakened by the tumor. Young people who are active in sports may initially mistake these symptoms for growing pains or sports injuries, which can delay proper diagnosis.
Parents and caregivers should be particularly attentive if symptoms persist beyond what would be expected from typical childhood injuries or growth spurts. Most osteosarcomas develop in the long bones near joints, especially around the knees, hips, or shoulders. The pain may come and go initially, becoming more constant over time. If these symptoms worry you or last more than a few weeks, it's advisable to make an appointment with a healthcare provider for proper evaluation.
People with certain risk factors should be especially vigilant about symptoms. Those who have previously received radiation therapy for other conditions, individuals with genetic conditions like Li-Fraumeni syndrome or hereditary retinoblastoma, and people with Paget's disease of bone have higher risks of developing osteosarcoma. Anyone in these groups experiencing bone-related symptoms should seek medical evaluation promptly.
When osteosarcoma is suspected, the diagnostic process typically begins with a thorough physical examination. During this exam, healthcare providers look for signs such as swelling, tenderness, limited range of motion in nearby joints, or visible lumps. They will ask detailed questions about when symptoms started, how they've progressed, and whether there's any family history of bone diseases or genetic conditions that might increase risk.
The next step usually involves imaging tests, which create pictures of the inside of the body to reveal abnormalities in bones. An X-ray is typically the first imaging test ordered because it can show areas where bone has been destroyed or where abnormal bone tissue has formed. X-rays are quick, widely available, and can often reveal the characteristic appearance of osteosarcoma tumors.
If an X-ray suggests a problem, more detailed imaging follows. Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves to create detailed images of soft tissues and bones. An MRI helps doctors see the exact size of the tumor and whether it has spread into nearby muscles, blood vessels, or nerves. This information is critical for planning surgery and understanding how extensive the tumor is within the affected area.
Computed tomography, commonly called a CT scan, is another important imaging tool. CT scans take multiple X-ray images from different angles and combine them to create cross-sectional views of bones and soft tissues. Doctors often use CT scans of the chest to check whether osteosarcoma has spread to the lungs, which is the most common site for this cancer to spread beyond the original bone.
A bone scan may be performed to determine if cancer has spread to other bones in the body. During this test, a small amount of radioactive material is injected into a vein, and then a special camera takes pictures of all the bones in the body. Areas with cancer typically show up as "hot spots" because they absorb more of the radioactive material than normal bone tissue.
Some medical centers also use positron emission tomography, or PET scans, which can show areas of active tumor growth throughout the body. PET scans work by detecting how cells in the body use sugar for energy – cancer cells typically use more sugar than normal cells, making them visible on the scan.
The biopsy procedure is the definitive diagnostic test for osteosarcoma. There are two main approaches: a needle biopsy, where a needle is inserted through the skin into the tumor to collect tissue samples, or a surgical biopsy, where a cut is made and tissue is removed through an incision. The choice depends on the tumor's location and size. A specialized doctor called a pathologist examines the biopsy sample under a microscope to look for cancer cells and determine the specific type and grade of osteosarcoma.
Special laboratory tests are performed on the biopsy tissue to provide additional information about the cancer cells. These tests can identify specific genetic changes or characteristics that help classify the exact type of osteosarcoma and may influence treatment decisions. Understanding whether the tumor is low-grade, intermediate-grade, or high-grade is essential, as this affects how aggressively the cancer is likely to grow and spread.
Blood tests are also part of the diagnostic workup, though they cannot diagnose osteosarcoma by themselves. Certain blood tests can measure levels of enzymes like alkaline phosphatase and lactate dehydrogenase, which may be elevated in people with osteosarcoma. These markers can sometimes help monitor how well treatment is working after diagnosis is confirmed.
When patients with osteosarcoma are being considered for enrollment in clinical trials, they typically undergo additional diagnostic evaluations beyond the standard tests. Clinical trials are research studies that test new treatments, and each trial has specific requirements, called eligibility criteria, that determine who can participate. Understanding these criteria helps patients and doctors decide whether a particular trial might be appropriate.
Most clinical trials for osteosarcoma require confirmation of the diagnosis through a biopsy that has been reviewed by a qualified pathologist. Trials may also specify that only certain subtypes of osteosarcoma are eligible. For example, some trials focus exclusively on high-grade conventional osteosarcoma, while others might include different variants. The biopsy tissue is often sent for additional specialized testing to confirm it meets the trial's requirements.
Imaging studies are crucial for clinical trial enrollment because trials typically specify whether the cancer must be localized (contained to one area) or metastatic (spread to other parts of the body). Patients usually need to have recent imaging – often within a few weeks before enrollment – showing exactly where tumors are located. This might include chest CT scans to document any lung metastases, bone scans to show if cancer has spread to other bones, and MRI scans of the primary tumor site.
Many trials require specific measurements of tumor size and characteristics. Doctors use standardized methods to measure tumors on imaging scans, creating a baseline that will be compared to future scans to determine if the treatment is working. Tumors must often meet minimum size requirements to be accurately measured and monitored throughout the study period.
Blood tests become particularly important for clinical trial qualification. Trials often require that patients have adequate organ function before starting experimental treatments. This means checking kidney function through blood tests that measure creatinine and blood urea nitrogen, checking liver function with tests for liver enzymes, and verifying blood cell counts to ensure the bone marrow is producing enough red blood cells, white blood cells, and platelets. These baseline values help ensure patients can safely tolerate the investigational treatment.
Heart function testing may be required for some clinical trials, especially those involving chemotherapy drugs known to affect the heart. An echocardiogram or a multigated acquisition scan (MUGA scan) measures how well the heart pumps blood and can detect any pre-existing heart problems that might be worsened by certain treatments. Trials may exclude patients whose heart function falls below a certain threshold.
Certain trials investigating targeted therapies or immunotherapies require additional specialized testing on tumor tissue. This might include tests to identify specific genetic mutations, measure levels of particular proteins on the cancer cell surface, or determine how many immune cells are present in and around the tumor. These tests help identify which patients are most likely to benefit from the specific treatment being studied.
Performance status assessment is another key component of clinical trial eligibility. Doctors use standardized scales to evaluate how well patients can perform daily activities and care for themselves. This assessment, while not a traditional diagnostic test, helps ensure that patients enrolled in trials are healthy enough to potentially benefit from and tolerate the experimental treatment being studied.
Documentation of previous treatments is essential for many clinical trial protocols. Patients may need detailed records showing exactly what chemotherapy drugs they received, what doses were given, when they had surgery, or whether they had radiation therapy. Some trials are designed for patients who haven't yet received any treatment, while others specifically seek patients whose cancer hasn't responded to standard therapies.
Several factors influence the outlook for people diagnosed with osteosarcoma. The most important factor is whether the cancer has spread beyond the original bone location at the time of diagnosis. When osteosarcoma is detected early and remains localized to one area, the chances of successful treatment are significantly better. The response to chemotherapy also plays a critical role in prognosis – tumors that shrink substantially with chemotherapy before surgery tend to have better outcomes.
The tumor's grade, which indicates how abnormal the cancer cells look under a microscope and how quickly they're likely to grow, affects prognosis as well. High-grade tumors are more aggressive and require more intensive treatment than low-grade tumors. The tumor's location matters too – osteosarcomas in certain bones may be easier to remove surgically with clear margins (meaning all cancer cells are removed), which improves outcomes.
Age at diagnosis can influence prognosis, with younger patients often having somewhat better outcomes than older adults. Advances in treatment over the past several decades have dramatically improved the outlook for osteosarcoma patients, particularly children and adolescents. Modern treatment combining surgery and chemotherapy has transformed what was once a frequently fatal disease into one where many patients can achieve long-term survival and even cure.
For patients with localized osteosarcoma – meaning the cancer hasn't spread beyond the bone where it started – survival rates have improved considerably. Approximately 60 to 70 percent of patients with localized disease survive at least five years after diagnosis when treated with modern therapy combining chemotherapy and surgery. Some sources indicate that around 7 in 10 people survive if the osteosarcoma doesn't spread to other parts of their bodies.
However, survival rates are notably lower when the cancer has already spread at diagnosis. Between 10 to 20 percent of patients present with metastases, most commonly to the lungs. For these patients with metastatic disease at diagnosis, the five-year survival rate drops considerably. Despite these challenges, advances in chemotherapy have meant that about two-thirds of children and adolescents with osteosarcoma can now achieve long-term cures, representing a major improvement compared to outcomes from decades ago.
It's important to remember that survival statistics are based on large groups of people and cannot predict exactly what will happen to any individual patient. Many factors unique to each person's situation can affect their actual outcome. Additionally, survival rates are based on data from patients treated years ago, and newer treatments may offer improved outcomes that aren't yet reflected in current statistics.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
